DE10346487A1 - Verfahren zur Herstellung eines Zell- und/oder Gewebe- und/oder Krankheitsphasen-spezifischen Arzneimittels - Google Patents

Verfahren zur Herstellung eines Zell- und/oder Gewebe- und/oder Krankheitsphasen-spezifischen Arzneimittels Download PDF

Info

Publication number
DE10346487A1
DE10346487A1 DE10346487A DE10346487A DE10346487A1 DE 10346487 A1 DE10346487 A1 DE 10346487A1 DE 10346487 A DE10346487 A DE 10346487A DE 10346487 A DE10346487 A DE 10346487A DE 10346487 A1 DE10346487 A1 DE 10346487A1
Authority
DE
Germany
Prior art keywords
cell
tissue
rna
dnazyme
target cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE10346487A
Other languages
English (en)
Inventor
Serdar Sel
Harald Renz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Philipps-Universitaet Marburg 35037 Marburg De
Original Assignee
Transmit Gesellschaft fuer Technologietransfer mbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transmit Gesellschaft fuer Technologietransfer mbH filed Critical Transmit Gesellschaft fuer Technologietransfer mbH
Priority to DE10346487A priority Critical patent/DE10346487A1/de
Priority to ES07013576T priority patent/ES2320706T3/es
Priority to US10/574,560 priority patent/US8119789B2/en
Priority to PT07013576T priority patent/PT1857555E/pt
Priority to CA2541240A priority patent/CA2541240C/en
Priority to EP07013576A priority patent/EP1857555B1/de
Priority to PL07013576T priority patent/PL1857555T3/pl
Priority to PL04802618T priority patent/PL1670919T3/pl
Priority to AT04802618T priority patent/ATE391788T1/de
Priority to DE502004006791T priority patent/DE502004006791D1/de
Priority to DK07013576T priority patent/DK1857555T3/da
Priority to SI200430734T priority patent/SI1670919T1/sl
Priority to PT04802618T priority patent/PT1670919E/pt
Priority to ES04802618T priority patent/ES2304633T3/es
Priority to JP2006529624A priority patent/JP5013870B2/ja
Priority to DE502004008802T priority patent/DE502004008802D1/de
Priority to AT07013576T priority patent/ATE419364T1/de
Priority to CA2776997A priority patent/CA2776997C/en
Priority to EP04802618A priority patent/EP1670919B1/de
Priority to PCT/DE2004/002197 priority patent/WO2005033314A2/de
Priority to DK04802618T priority patent/DK1670919T3/da
Priority to KR1020067008072A priority patent/KR101121818B1/ko
Publication of DE10346487A1 publication Critical patent/DE10346487A1/de
Priority to CY20081100675T priority patent/CY1108161T1/el
Priority to JP2011005485A priority patent/JP5291129B2/ja
Priority to US13/037,411 priority patent/US8247544B2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)

Abstract

Die vorliegende Erfindung betrifft ein Verfahren zur Herstellung eines Zell- und/oder Gewebe- und/oder Krankheitsphasen-spezifischen Arzneimittels gegen chronische Entzündungserkrankungen. DOLLAR A Dabei werden Krankheits-, Zelltyp-, Gewebe- und/oder stadienspezifische Proteine und Nukleinsäuren hinsichtlich ihres geänderten Expressionsmusters identifiziert und die entsprechenden Nukleinsäuren als mögliche Angriffsziele für DNAzyme oder siRNA analysiert. Es folgt ein Design von aktiven spezifischen DNAzymen und siRNA, die an die Zielsequenz binden und diese spalten, so dass ein Arzneimittel gegen chronische Entzündungserkrankungen und Autoimmunerkrankungen zur Verfügung steht.
DE10346487A 2003-10-02 2003-10-02 Verfahren zur Herstellung eines Zell- und/oder Gewebe- und/oder Krankheitsphasen-spezifischen Arzneimittels Withdrawn DE10346487A1 (de)

Priority Applications (25)

Application Number Priority Date Filing Date Title
DE10346487A DE10346487A1 (de) 2003-10-02 2003-10-02 Verfahren zur Herstellung eines Zell- und/oder Gewebe- und/oder Krankheitsphasen-spezifischen Arzneimittels
ES04802618T ES2304633T3 (es) 2003-10-02 2004-10-01 Procedimiento para la preparacion de un farmaco especifico para celulas y/o tejidos y/o fases de enfermedad.
JP2006529624A JP5013870B2 (ja) 2003-10-02 2004-10-01 細胞および／または組織および／または疾患フェーズ特異的な薬剤の製造方法
US10/574,560 US8119789B2 (en) 2003-10-02 2004-10-01 Method for the production of a cell and/or tissue and/or disease phase specific medicament
DE502004008802T DE502004008802D1 (de) 2003-10-02 2004-10-01 Verfahren zur Herstellung eines Zell- und/oder Gewebe- und/oder Krankheitsphasen-spezifischen Arzneimittels
EP07013576A EP1857555B1 (de) 2003-10-02 2004-10-01 Verfahren zur Herstellung eines Zell- und/oder Gewebe- und/oder Krankheitsphasen-spezifischen Arzneimittels
PL07013576T PL1857555T3 (pl) 2003-10-02 2004-10-01 Sposób wytwarzania leku specyficznego dla komórki i/lub tkanki i/lub fazy choroby
PL04802618T PL1670919T3 (pl) 2003-10-02 2004-10-01 Sposób wytwarzania leku działającego swoiście na komórki i/lub tkanki i/lub wybrane fazy choroby
AT04802618T ATE391788T1 (de) 2003-10-02 2004-10-01 Verfahren zur herstellung eines zell- und/oder gewebe- und/oder krankheitsphasen-spezifischen arzneimittels
DE502004006791T DE502004006791D1 (de) 2003-10-02 2004-10-01 Verfahren zur herstellung eines zell- und/oder gewebe- und/oder krankheitsphasen-spezifischen arzneimittels
DK07013576T DK1857555T3 (da) 2003-10-02 2004-10-01 Fremgangsmåde til fremstilling af et celle- og/eller vævs- og/eller sygdomsfase-specifikt lægemiddel
SI200430734T SI1670919T1 (sl) 2003-10-02 2004-10-01 Metoda za pripravo celic in/ali tkiva in/ali bolezni specifiäśno zdravilo
PT04802618T PT1670919E (pt) 2003-10-02 2004-10-01 Processo para a preparação de um medicamento específico para as células e/ou tecidos e/ou fases de doenças
ES07013576T ES2320706T3 (es) 2003-10-02 2004-10-01 Procedimiento para la produccion de un medicamento especifico para celulas y/o tejidos y/o fases de enfermedad.
PT07013576T PT1857555E (pt) 2003-10-02 2004-10-01 Processo para a produção de um medicamento específico de células e/ou de tecidos e/ou de estádios patológicos
CA2541240A CA2541240C (en) 2003-10-02 2004-10-01 Method for the production of a cell and/or tissue and/or disease phase specific medicament
AT07013576T ATE419364T1 (de) 2003-10-02 2004-10-01 Verfahren zur herstellung eines zell- und/oder gewebe- und/oder krankheitsphasen-spezifischen arzneimittels
CA2776997A CA2776997C (en) 2003-10-02 2004-10-01 Method for the production of a cell and/or tissue and/or disease phase specific medicament
EP04802618A EP1670919B1 (de) 2003-10-02 2004-10-01 Verfahren zur herstellung eines zell- und/oder gewebe- und/oder krankheitsphasen-spezifischen arzneimittels
PCT/DE2004/002197 WO2005033314A2 (de) 2003-10-02 2004-10-01 Verfahren zur herstellung eines zell- und/oder gewebe- und/oder krankheitsphasen-spezifischen arzneimittels
DK04802618T DK1670919T3 (da) 2003-10-02 2004-10-01 Fremgangsmåde til fremstilling af et cellespecifikt og/eller vævsspecifikt og/eller sygdomsfasespecifikt lægemiddel
KR1020067008072A KR101121818B1 (ko) 2003-10-02 2004-10-01 세포 및/또는 조직 및/또는 질환 단계 특이적 의약품의제조 방법
CY20081100675T CY1108161T1 (el) 2003-10-02 2008-06-27 Μεθοδος για την παραγωγη φαρμακευτικου μεσου με κυτταρικη ειδικοτητα και/ή ιστικη ειδικοτητα και/ή ειδικοτητα φασης νοσου
JP2011005485A JP5291129B2 (ja) 2003-10-02 2011-01-14 細胞および／または組織および／または疾患フェーズ特異的な薬剤の製造方法
US13/037,411 US8247544B2 (en) 2003-10-02 2011-03-01 Method for producing a cell and/or tissue and/or disease phase specific medicament

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10346487A DE10346487A1 (de) 2003-10-02 2003-10-02 Verfahren zur Herstellung eines Zell- und/oder Gewebe- und/oder Krankheitsphasen-spezifischen Arzneimittels

Publications (1)

Publication Number Publication Date
DE10346487A1 true DE10346487A1 (de) 2005-05-12

Family

ID=34399325

Family Applications (3)

Application Number Title Priority Date Filing Date
DE10346487A Withdrawn DE10346487A1 (de) 2003-10-02 2003-10-02 Verfahren zur Herstellung eines Zell- und/oder Gewebe- und/oder Krankheitsphasen-spezifischen Arzneimittels
DE502004008802T Expired - Lifetime DE502004008802D1 (de) 2003-10-02 2004-10-01 Verfahren zur Herstellung eines Zell- und/oder Gewebe- und/oder Krankheitsphasen-spezifischen Arzneimittels
DE502004006791T Expired - Lifetime DE502004006791D1 (de) 2003-10-02 2004-10-01 Verfahren zur herstellung eines zell- und/oder gewebe- und/oder krankheitsphasen-spezifischen arzneimittels

Family Applications After (2)

Application Number Title Priority Date Filing Date
DE502004008802T Expired - Lifetime DE502004008802D1 (de) 2003-10-02 2004-10-01 Verfahren zur Herstellung eines Zell- und/oder Gewebe- und/oder Krankheitsphasen-spezifischen Arzneimittels
DE502004006791T Expired - Lifetime DE502004006791D1 (de) 2003-10-02 2004-10-01 Verfahren zur herstellung eines zell- und/oder gewebe- und/oder krankheitsphasen-spezifischen arzneimittels

Country Status (14)

Country Link
US (2) US8119789B2 (de)
EP (2) EP1857555B1 (de)
JP (2) JP5013870B2 (de)
KR (1) KR101121818B1 (de)
AT (2) ATE391788T1 (de)
CA (2) CA2776997C (de)
CY (1) CY1108161T1 (de)
DE (3) DE10346487A1 (de)
DK (2) DK1857555T3 (de)
ES (2) ES2320706T3 (de)
PL (2) PL1670919T3 (de)
PT (2) PT1670919E (de)
SI (1) SI1670919T1 (de)
WO (1) WO2005033314A2 (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102010007562A1 (de) 2010-02-10 2011-08-11 sterna biologicals GmbH & Co KG, 35043 Dermatologische, pharmazeutische Zusammensetzung geeignet für Oligonukleotide
EP3501607A1 (de) 2017-12-22 2019-06-26 Sterna Biologicals GmbH & Co. KG Zusammensetzung zur behandlung eines an einer mit chronischen entzündungen einhergehenden atemwegserkrankung leidenden patienten sowie herstellungsverfahren und verwendung der zusammensetzung

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI322690B (en) 2006-05-11 2010-04-01 Flysun Dev Co Ltd Short interference ribonucleic acids for treating allergic dieases
US20120029054A1 (en) * 2009-03-19 2012-02-02 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of GATA Binding Protein 3 (GATA3) Gene Expression Using Short Intefering Nucleic Acid (siNA)
WO2010110314A1 (ja) * 2009-03-27 2010-09-30 協和発酵キリン株式会社 核酸を含有する肺高血圧症治療剤
DE102010056610A1 (de) * 2010-12-31 2012-07-05 Volker A. Erdmann Pharmazeutische Zusammensetzung enthaltend L-DNA
DE102011109868A1 (de) * 2011-08-10 2013-02-14 STERNA BIOLOGICALS GmbH & Co. KG. Multiple Emulsion
EP2708898A1 (de) 2012-09-14 2014-03-19 Sterna Biologicals GmbH & Co. Kg Verfahren zur Diagnose eines molekularen Phänotyps eines an einer mit chronischen Entzündungen einhergehenden Erkrankung leidenden Patienten
SI3093022T1 (sl) * 2015-05-15 2019-12-31 Sterna Biologicals Gmbh & Co. Kg GATA-3 inhibitorji za uporabo pri zdravljenju astme, ki jo povzroča TH2
JP7065778B2 (ja) 2016-02-26 2022-05-12 セカルナ・ファーマシューティカルズ・ゲーエムベーハー・ウント・コ・カーゲー 炎症性障害を処置するための新規なアプローチ
EP3211081A1 (de) 2016-02-26 2017-08-30 Secarna Pharmaceuticals GmbH & Co. KG Neuartiger ansatz zur behandlung von entzündlichen erkrankungen
US10905710B2 (en) 2016-05-24 2021-02-02 Emory University Particles with RNA cleaving nucleobase polymers and uses for managing inflammatory disorders
ES2973216T3 (es) 2018-01-18 2024-06-19 Sterna Biologicals Gmbh Composición para el tratamiento de un paciente que padece colitis ulcerosa y uso de la composición como medicamento
WO2019171191A1 (en) * 2018-03-05 2019-09-12 Dr. Reddy's Institute Of Life Sciences Embryonic zebrafish models using dnazyme mediated knockdown
EP3603617A1 (de) 2018-07-30 2020-02-05 Sterna Biologicals GmbH & Co. KG Aerosolerzeugungseinrichtung zur inhalativen verabreichung einer antisense-molekül-haltigen zusammensetzung
EP3805242A1 (de) 2019-10-07 2021-04-14 Sterna Biologicals GmbH & Co. KG Verfahren zur herstellung eines katalytisch aktiven dna-moleküls mit verbesserter aktivität und dessen verwendung in einem verfahren zur behandlung von asthma
US11976282B2 (en) 2020-06-23 2024-05-07 Qatar University GATA3 inhibitors for the promotion of subcutaneous fat deposition
WO2022144883A2 (en) 2020-12-28 2022-07-07 1E Therapeutics, Ltd. P21 mrna targeting dnazymes
AU2021411103A1 (en) 2020-12-28 2023-07-13 1E Therapeutics, Ltd. P21 mrna target areas for silencing
WO2023052422A1 (en) 2021-09-30 2023-04-06 Sterna Biologicals Gmbh Dnazyme hydrogel formulations

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999050452A1 (en) * 1998-03-27 1999-10-07 Johnson & Johnson Research Pty. Limited Catalytic nucleic acid-based diagnostic methods
WO2001011023A1 (en) * 1999-08-04 2001-02-15 Johnson & Johnson Research Pty Ltd Treatment of inflammatory or malignant disease using dnazymes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010072475A (ko) * 1998-08-13 2001-07-31 추후제출 재발협착증을 치료하기 위한 ｄｎａ자임 및 치료 방법
AUPP810399A0 (en) * 1999-01-11 1999-02-04 Unisearch Limited Catalytic molecules
IL145034A0 (en) * 1999-03-05 2002-06-30 Epigenesis Pharmaceuticals Inc Method for validating/invalidating target(s) and pathways
WO2002068637A2 (en) * 2000-10-20 2002-09-06 Ribozyme Pharmaceuticals, Inc. Nucleic acid-based treatment of diseases or conditions related to west nile virus infection
US20030148971A1 (en) * 2002-02-04 2003-08-07 Handel Malcolm Lovell Treatment of inflammatory and malignant diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999050452A1 (en) * 1998-03-27 1999-10-07 Johnson & Johnson Research Pty. Limited Catalytic nucleic acid-based diagnostic methods
WO2001011023A1 (en) * 1999-08-04 2001-02-15 Johnson & Johnson Research Pty Ltd Treatment of inflammatory or malignant disease using dnazymes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FINOTTO,Susetta, et.al.: Treatment of Allergic Airway Inflammation and Hyperresponsiveness by Antisense-induced Local Blockade of GATA-3 Expression. In: J. Exp. Med., Vol.193 (11), S.1247-1260 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102010007562A1 (de) 2010-02-10 2011-08-11 sterna biologicals GmbH & Co KG, 35043 Dermatologische, pharmazeutische Zusammensetzung geeignet für Oligonukleotide
WO2011098285A2 (de) 2010-02-10 2011-08-18 Sterna Biologicals Gmbh & Co. Kg Dermatologische, pharmazeutische zusammensetzung geeignet für oligonukleotide
EP2533763A2 (de) * 2010-02-10 2012-12-19 Sterna Biologicals GmbH & Co. Kg Dermatologische, pharmazeutische zusammensetzung geeignet für oligonukleotide
US9249413B2 (en) 2010-02-10 2016-02-02 Sterna Biologicals Gmbh & Co. Kg Dermatological, pharmaceutical composition suitable for oligonucleotides
US9404110B2 (en) 2010-02-10 2016-08-02 Sterna Biologicals Gmbh & Co. Kg Dermatological, pharmaceutical composition suitable for oligonucleotides
EP2533763B1 (de) * 2010-02-10 2023-07-12 Sterna Biologicals GmbH Dermatologische, pharmazeutische zusammensetzung geeignet für oligonukleotide
EP3501607A1 (de) 2017-12-22 2019-06-26 Sterna Biologicals GmbH & Co. KG Zusammensetzung zur behandlung eines an einer mit chronischen entzündungen einhergehenden atemwegserkrankung leidenden patienten sowie herstellungsverfahren und verwendung der zusammensetzung
WO2019122267A1 (de) 2017-12-22 2019-06-27 Sterna Biologicals Gmbh & Co. Kg Zusammensetzung zur behandlung eines an einer mit chronischen entzündungen einhergehenden atemwegserkrankung leidenden patienten sowie herstellungsverfahren und verwendung der zusammensetzung
CN111683718A (zh) * 2017-12-22 2020-09-18 燕鸥生物制剂有限两合公司 用于治疗患有慢性炎症引发的呼吸道疾病的患者的组合物以及该组合物的制备方法和用途

Also Published As

Publication number Publication date
SI1670919T1 (sl) 2008-08-31
CA2776997A1 (en) 2005-04-14
DE502004006791D1 (de) 2008-05-21
JP2011074089A (ja) 2011-04-14
JP5291129B2 (ja) 2013-09-18
EP1670919A2 (de) 2006-06-21
EP1857555B1 (de) 2008-12-31
DK1670919T3 (da) 2008-07-14
US8119789B2 (en) 2012-02-21
EP1857555A1 (de) 2007-11-21
US20110190377A1 (en) 2011-08-04
ES2320706T3 (es) 2009-05-27
US20100249216A1 (en) 2010-09-30
KR20060120048A (ko) 2006-11-24
ES2304633T3 (es) 2008-10-16
WO2005033314A2 (de) 2005-04-14
PL1857555T3 (pl) 2009-06-30
CA2541240A1 (en) 2005-04-14
CA2541240C (en) 2014-06-03
PT1857555E (pt) 2009-04-07
DK1857555T3 (da) 2009-05-04
JP5013870B2 (ja) 2012-08-29
ATE391788T1 (de) 2008-04-15
PL1670919T3 (pl) 2008-10-31
CA2776997C (en) 2015-05-19
EP1670919B1 (de) 2008-04-09
CY1108161T1 (el) 2014-02-12
JP2007507438A (ja) 2007-03-29
WO2005033314A3 (de) 2005-09-01
DE502004008802D1 (de) 2009-02-12
KR101121818B1 (ko) 2012-06-12
ATE419364T1 (de) 2009-01-15
US8247544B2 (en) 2012-08-21
PT1670919E (pt) 2008-07-17

Similar Documents

Publication Publication Date Title
DE10346487A1 (de) Verfahren zur Herstellung eines Zell- und/oder Gewebe- und/oder Krankheitsphasen-spezifischen Arzneimittels
Fang et al. MicroRNAs regulate bone development and regeneration
Tsimbouri et al. Using nanotopography and metabolomics to identify biochemical effectors of multipotency
Lister et al. Turning over DNA methylation in the mind
Campbell et al. Gene expression profile of the regeneration epithelium during axolotl limb regeneration
Zhang et al. Stem cells for modeling and therapy of Parkinson's disease
Stimpfel et al. New challenge: mitochondrial epigenetics?
Li et al. Upregulation of lncRNA VDR/CASC15 induced by facilitates cardiac hypertrophy through modulating miR-432-5p/TLR4 axis
Salinas et al. Shear stress induced by fluid flow produces improvements in tissue-engineered cartilage
Sada et al. Near-IR laser-triggered target cell collection using a carbon nanotube-based cell-cultured substrate
Zhou et al. Targeting RNA-splicing for SMA treatment
Kim et al. Raman spectroscopy-based 3D analysis of odontogenic differentiation of human dental pulp stem cell spheroids
Gearhart et al. Identification of conserved and novel microRNAs during tail regeneration in the Mexican Axolotl
Bobkova et al. Neuroregeneration: regulation in neurodegenerative diseases and aging
Han et al. Ribosomes: an exciting avenue in stem cell research
Kour et al. Interplay between circular RNA, microRNA, and human diseases
Zhu et al. Epigenetic regulation of organ regeneration in zebrafish
Tan et al. Non-coding RNAs in the regulation of hippocampal neurogenesis and potential treatment targets for related disorders
Brito et al. MicroRNA-138: an emerging regulator of skeletal development, homeostasis, and disease
Gjaltema et al. KRAB-induced heterochromatin effectively silences PLOD2 gene expression in somatic cells and is resilient to TGFβ1 activation
Brzin et al. Cholinesterases
CN108148836A (zh) 一种肝再生相关长链非编码rna及其抑制剂和应用
WO2015002892A1 (en) Methods of treating diseases by modulating mitochondrial dna deletions
Qiao et al. miR-328a-3p modulates the proliferative and migratory abilities of Schwann cells in peripheral nerves
Mathis et al. Light-Controlled Cell–Cell Assembly Using Photocaged Oligonucleotides

Legal Events

Date Code Title Description
OM8 Search report available as to paragraph 43 lit. 1 sentence 1 patent law
8127 New person/name/address of the applicant

Owner name: PHILIPPS-UNIVERSITAET MARBURG, 35037 MARBURG, DE

8141 Disposal/no request for examination